New research on almonds, UTIs and cancer
December 1, 2022 | View PDF
Almonds may pack important hidden health benefit
Eating a handful of almonds a day can greatly benefit your tummy because almonds significantly increase the production of butyrate, a short-chain fatty acid that promotes gut health, according to a recent study. A team of researchers from King’s College London investigated the impact of whole and ground almonds on the composition of gut microbes.
The gut microbiome consists of thousands of microorganisms living in the gut. These play a vital role in digesting nutrients and can have a positive or negative influence on our health, including our digestive and immune systems. The mechanisms of how the gut microbiomes have an impact on human health is still being investigated, but evidence suggests eating specific types of food can positively influence the types of bacteria in our gut.
Researchers recruited 87 healthy adults who were already eating less than the recommended amount of dietary fiber and who snacked on typical unhealthy snacks, such as potato chips. Participants were split into three groups: One group changed their snacks for 56 grams of whole almonds a day, another for 56 grams of ground almonds a day, and the control group ate energy-matched muffins. The trial lasted four weeks.
Researchers found that butyrate was significantly higher among almond eaters compared to those who consumed the muffin. Butyrate is a short-chain fatty acid that is the main source of fuel for the cells lining the colon. When these cells function effectively, it provides an ideal condition for gut microbes to flourish, for the gut wall to be strong and not leaky or inflamed and for nutrients to be absorbed.
No significant difference was observed in gut transit time, which is the time it takes for food to move all the way through the gut. However whole-almond eaters had an additional 1.5 bowel movements per week compared to the other groups. These findings, published in the American Journal of Clinical Nutrition, suggest eating almonds could also benefit those with constipation.
Testing showed that eating whole and ground almond improved peoples’ diets, having higher intakes of monounsaturated fatty acids, fiber, potassium and other important nutrients compared to the control group.
“We think these findings suggest almond consumption may benefit bacterial metabolism in a way that has the potential to influence human health,” said lead author Kevin Whelan, Head of Department of Nutritional Sciences at King’s College London, UK.
New drug combination for combating urinary tract infections
Finally, a new weapon against UTIs. An international study comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.
Research from the ALLIUM Phase 3 clinical trial showed that a combination of the drugs cefepime and enmetazobactam was more effective in treating both complicated urinary tract infections and acute pyelonephritis (AP), a bacterial infection causing kidney inflammation. It appeared to have significant benefits over the standard treatment combining piperacillin and tazobactam. UTIs are considered complicated when they are associated with fevers, sepsis, or urinary obstructions.
“It represents an exciting option for treatment,” said lead study author Keith Kaye, chief of the Division of Allergy, Immunology and Infectious Diseases and a professor of medicine at Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
The trial was conducted at 90 sites in Europe, North and Central America, South America and South Africa from September 2018 to November 2019. More than 1,000 patients participated in the study. The researchers found that 79% of the patients receiving the new combination of cefepime and enmetazobactam were successfully treated for their illness compared to 59% of those receiving the conventional treatment of piperacillin and tazobactam.
The antibiotic cefepime is a fourth-generation cephalosporin that was approved for use in the 1990s and is available generically. Enmetazobactam, an experimental drug made by the French biopharmaceutical company Allecra Therapeutics, is a beta-lactamase inhibitor. More than 2.8 million
antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die from them, according to a report from the U.S. Centers for Disease Control and Prevention (CDC).
Good news in the war on cancer
Overall cancer death rates are continuing to decline among men, women, children and adolescents in every major racial and ethnic group in the United States. The latest numbers are from 2015 to 2019 and are published in the Annual Report to the Nation on the Status of Cancer.
All of the findings in this report are based on data from before the COVID-19 pandemic. The report shows that from 2015 to 2019, overall cancer death rates decreased by 2.1% per year in men and women combined. Among men, death rates decreased by 2.3% per year. Among women, death rates decreased by 1.9% per year. The annual declines in death rate accelerated from 2001 to 2019 in both men and women.
The declines in death rates were steepest in lung cancer and melanoma (by 4% to 5% per year) among both men and women. Death rates increased for cancers of the pancreas, brain and bones and joints among men, and for cancers of the pancreas and uterus among women.
“The findings in this year’s Annual Report to the Nation show our ongoing progress against cancer, continuing a more than two-decade trend in declining mortality that reflects improvements in preventing, detecting, and treating cancer,” said Dr. Monica M. Bertagnolli, director of the National Cancer Institute (NCI).
In men, the greatest incidence rate increase was seen in pancreatic cancer, which increased by 1.1% per year, and the steepest incidence rate decrease was seen in lung cancer, which fell by 2.6% per year. In women, melanoma had the steepest increase in incidence, rising by 1.8% per year, and thyroid cancer had the sharpest decrease, falling by 2.9% per year.
“Through funding scientific breakthroughs and raising awareness about prevention and early detection, we are making progress against a subset of the more than 200 diseases we call cancer,” said Karen E. Knudsen, chief executive officer of the American Cancer Society. “However, for certain cancer types, concerning trends persist, and durable cures remain elusive for many people.”
John Schieszer is an award-winning national journalist and radio and podcast broadcaster of The Medical Minute. He can be reached at firstname.lastname@example.org.